Can a targeted drug boost standard chemo for an aggressive lymphoma?

NCT ID NCT04263584

Completed Disease control Sponsor: University Hospital Muenster Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 trial is investigating whether adding the targeted drug copanlisib to the standard R-CHOP chemoimmunotherapy regimen can help people with previously untreated diffuse large B-cell lymphoma (DLBCL) live longer without their cancer progressing. The study enrolls adults aged 18 to 80 with certain types of aggressive B-cell lymphoma. Researchers are measuring how long participants remain free of disease progression, as well as overall survival and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: copanlisib added to standard R-CHOP chemotherapy
What this could lead to: If successful, this combination could offer a more effective first-line treatment for diffuse large B-cell lymphoma, potentially improving the chance of long-term remission.
What could go wrong: This is an early-phase, single-group trial with no placebo or comparison group, so any benefit is uncertain. Adding copanlisib may also increase side effects like infections or organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Haematology and Oncology Practice

Augsburg, 86150, Germany
Hospital Stuttgart - Stuttgart Cancer Center

Stuttgart, 70174, Germany
Hospital of the Ludwig-Maximilians-University (LMU) Munich

Munich, 81377, Germany
Karlsruhe City Hospital

Karlsruhe, 76133, Germany
Klinikum-Bremen-Mitte

Bremen, 28205, Germany
Ludwigshafen City Hospital

Ludwigshafen, 67063, Germany
Onkozentrum Dresden

Dresden, 01127, Germany
St.-Johannes-Hospital Dortmund

Dortmund, 44137, Germany
University Hospital Halle

Halle, 06120, Germany
University Hospital Leipzig

Leipzig, 04103, Germany
University Hospital Muenster

Münster, 48149, Germany
University Hospital RWTH Aachen

Aachen, 52074, Germany
University Hospital Ulm

Ulm, 89081, Germany
University Medical Center Hamburg-Eppendorf

Hamburg, 20246, Germany
Westpfalz-Klinikum

Kaiserslautern, 67655, Germany
ÜBAG MVZ Dr. Vehling-Kaiser GmbH

Landshut, 84036, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.